EVENITY
PeakmAbBLAINJECTIONINJECTABLE
Approved
Apr 2019
Lifecycle
Peak
Competitive Pressure
30/100
Clinical Trials
9
Data completeness
7/8 — Comprehensive
EVENITY by Amgen is sclerostin, a regulatory factor in bone metabolism. Approved for osteoporosis in postmenopausal women at high risk for fracture, defined, multiple risk factors for fracture. First approved in 2019.
Drug data last refreshed 22h ago · AI intelligence enriched 1mo ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
EVENITY (romosozumab-aqqg) is a monoclonal antibody developed by Amgen for the treatment of osteoporosis in postmenopausal women at high risk of fracture. It works by inhibiting sclerostin, a protein that suppresses bone formation, thereby increasing bone density and reducing fracture risk. The drug is administered via subcutaneous injection.
$0.001BPart D
PeakEVENITY is at peak commercial stage with moderate Medicare utilization (440 Part D claims in 2023), suggesting an established but niche market position within the osteoporosis category.
Mechanism of Action
sclerostin, a regulatory factor in bone metabolism. EVENITY increases bone formation and, to a lesser extent, decreases bone resorption. Animal studies showed that romosozumab-aqqg stimulates new bone formation on trabecular and cortical bone surfaces by stimulating osteoblastic activity resulting…
Worked on EVENITY at Amgen? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.